stockrow
Friday 6 November 2026
Export RLAY’s income statement to Excel — free account
Relay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +13.3%
- Free cash flow
- +2.13%
Quarter to September 2026, against a year earlier
18.44
1.44
+8.47%
Follow RLAY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
57.24 | 97.49 | 344.21 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(32.36) | (35.01) | (70.14) | — | |
P/B ratio |
2.56 | 2.79 | 4.26 | — | |
Price to Tangible BV |
2.57 | 2.80 | 4.28 | — | |
EV/Sales |
35.37 | 62.51 | 261.60 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(3.81) | (5.38) | (13.59) | — | |
EV/FCF |
(3.80) | (5.37) | (13.57) | — | |
Quick Ratio |
21.68 | 21.58 | 17.93 | 14.35 | |
Current Ratio |
22.61 | 22.13 | 18.27 | 14.62 | |
Net Debt/EBITDA |
9.11 | 8.14 | 10.00 | 9.34 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.02 | 0.01 | 0.00 | |
Operating CF/Net income |
0.82 | 0.70 | 0.65 | 0.78 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
791.76% | 2,352.10% | 21,852.29% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
174.52% | 367.57% | 4,197.43% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
186.70% | 351.23% | 2,622.57% | 0.00% | |
Graham Net Nets |
0.36 | 0.34 | 0.22 | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(19.15%) | (15.78%) | (8.39%) | — | |
Free Cash Flow Yield |
(16.25%) | (11.95%) | (5.60%) | — | |
Revenue per Share |
0.04 | 0.02 | 0.00 | 0.00 | |
Operating CF per Share |
(0.26) | (0.28) | (0.27) | (0.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.26) | (0.28) | (0.27) | (0.29) | |
Cash per Share |
3.23 | 3.57 | 4.49 | 3.87 | |
Shareholders Equity per Share |
3.30 | 3.57 | 4.39 | 3.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.30 | 3.57 | 4.39 | 3.74 | |
Free Cash Flow |
(44.87) | (51.11) | (54.11) | (63.93) | |
Working Capital |
552.70 | 628.71 | 877.28 | 805.70 | |
Capital Expenditures |
0.00 | — | — | — | |
Net Current Asset Value |
524.01 | 601.03 | 850.63 | 782.15 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Payables |
10.90 | 6.28 | 8.32 | 5.97 | |
Average Assets |
746.31 | 749.49 | 848.15 | 785.85 | |
Average Common Equity |
672.43 | 681.63 | 777.83 | 713.35 |
Columns are period end dates · fundamentals updated 6 Nov 2026